Perimenopause and menopause affect nearly everything: sleep, weight, mood, cognition, cardiovascular health, bone density. Most doctors address symptoms one at a time. Dr. Lampert evaluates the full picture and builds a treatment plan around what's actually going on.
Dr. Seth Lampert, MDFounding Physician and Medical Director
Tufts University School of Medicine
Your symptoms, your history, your labs, your risk factors. Dr. Lampert evaluates menopause as a whole-body physiologic transition, including its effects on sleep, body composition, bone health, cardiovascular risk and quality of life.
The right formulation, the right dose, the right route. Estrogen, progesterone, and other therapies as clinically indicated. Adjusted based on how you respond, not a protocol sheet.
One doctor from evaluation through treatment. Not a rotating panel. Not a nurse practitioner relay. Dr. Lampert manages your care directly.
Most people think of menopause as something that happens at 50. Hot flashes, maybe some night sweats. It's treated as a temporary inconvenience. That misunderstanding causes real harm.
Perimenopause typically begins in the early-to-mid 40s, sometimes earlier. Estrogen and progesterone don't decline in a straight line. They fluctuate unpredictably, sometimes wildly, for years before periods stop. During that time, women experience symptoms that are genuinely disabling: severe sleep disruption, abdominal weight gain that doesn't respond to diet or exercise, brain fog that makes it difficult to work, anxiety that appears out of nowhere, joint pain, loss of libido, mood changes that feel like a different person showed up.
Hormonal changes can contribute meaningfully to these symptoms, but they can also overlap with thyroid disease, sleep disorders, depression, medication effects and other conditions. A good evaluation considers both menopause and the alternatives. Yet for millions of women, none of that evaluation happens.
Here's why. Many physicians still rely on lab reference ranges that define "normal" as any value that falls within the range for your age group. A 46-year-old woman with estradiol levels that have declined significantly from her personal baseline can still fall within the "normal" reference range. Her symptoms are real. Her labs say she's fine. So she's told she's stressed, or offered an antidepressant, or told to wait it out.
Illustrative example: Consider a 47-year-old woman who has seen three doctors over two years. Her primary care physician orders a basic hormone panel and says everything is normal. An OB-GYN suggests an antidepressant for mood changes. A naturopath recommends supplements. She is sleeping four hours a night, has gained 18 pounds despite eating less and exercising more than in her 30s, and her thinking feels slow.
In a scenario like this, the issue may be perimenopause. Estradiol can fluctuate between levels that cause symptoms in most women, while each individual draw happens to land in the reference range. When transdermal estradiol and micronized progesterone are appropriate and initiated, improvements in sleep, weight stability, and cognition can follow within weeks to months. The issue is often not complicated. It is just being missed.
Illustrative example. Not a specific patient. Individual evaluation and results vary.The symptoms that bring most patients to this practice: hot flashes and night sweats. Sleep disruption. Weight gain, especially around the midsection. Cognitive changes and difficulty concentrating. Mood instability and new-onset anxiety. Low or absent libido. Joint pain and stiffness. Vaginal dryness. Fatigue that doesn't improve with rest.
If you've been experiencing several of these and haven't gotten a satisfactory answer, you're not imagining it.
This is clinical medicine, not guesswork. Every patient gets a thorough evaluation. The treatment plan follows from what that evaluation reveals.
Hormone therapy is not for everyone. It's also not the dangerous intervention it was made out to be for a decade. The truth is more specific than either extreme.
In 2002, the Women's Health Initiative (WHI) published results that were widely interpreted as showing that HRT causes breast cancer and heart disease. The study made national headlines. Millions of women stopped their hormones. Physicians stopped prescribing. An entire generation of doctors was trained to avoid HRT almost categorically.
The problem is that the headlines didn't match the data. The WHI studied predominantly older women (average age 63) who started hormone therapy more than a decade after menopause. Subsequent reanalysis, and over two decades of additional research, showed a very different picture for younger, symptomatic women. For most healthy women with bothersome menopausal symptoms who begin hormone therapy before age 60 or within 10 years of menopause onset, major menopause societies consider the benefit-risk profile favorable when treatment is individualized. This is now the position of the Endocrine Society, the North American Menopause Society (NAMS), and ACOG.
Specifically: transdermal estradiol (patches, gels) appears to have a lower clotting risk than oral estrogen. Micronized progesterone has a better safety profile than the synthetic progestin used in the WHI. Hormone therapy is not recommended for the sole purpose of cardiovascular prevention, but for healthy symptomatic women younger than 60 or within 10 years of menopause onset, the benefit-risk ratio is generally favorable for treating bothersome symptoms and preventing bone loss.
Dr. Lampert's approach is individualized risk-benefit analysis. Not blanket rules, not ideology. If hormone therapy is appropriate for you, he'll explain why. If it isn't, he'll explain that too, and discuss alternatives.
Hormone therapy requires a physician who understands cardiovascular risk, cancer screening, metabolic health, and drug interactions. Dr. Lampert evaluates the full clinical picture before prescribing. Menopause is not an aesthetic concern. It's a metabolic transition that deserves real medical judgment.
Platforms that run a questionnaire and ship hormones are not providing medical care. Hormone therapy requires monitoring, dose adjustment, and a physician who knows your history and is available when symptoms change. You see the same doctor every time.
Hormonal changes during menopause interact with thyroid function, insulin sensitivity, body composition, cardiovascular risk, and bone density. Dr. Lampert integrates menopause care with weight management, metabolic health, and other treatments as needed. One physician managing the full picture, not five specialists who don't talk to each other.
"The difference between a prescription and a physician."
Wellesley Medical
Medications purchased separately through your pharmacy. Additional testing beyond baseline available at discounted rates.
Not always. Menopause is primarily a clinical diagnosis based on symptoms and history, not lab values. ACOG guidance is clear that routine hormone testing is not required to diagnose menopause or initiate therapy in most cases. Dr. Lampert orders targeted labs when they will actually change the treatment plan, such as thyroid function, metabolic markers, or hormone levels when the clinical picture is ambiguous. Testing should serve a purpose, not just generate data.
Dr. Lampert prescribes FDA-approved estrogen (transdermal patch, oral, topical cream or gel) and micronized progesterone. Testosterone may be considered in selected postmenopausal women with hypoactive sexual desire disorder after appropriate evaluation; there is no FDA-approved testosterone product for women. The specific formulation, route, and dose depend on your symptoms, medical history, and risk profile. He does not default to compounded bioidentical hormones. FDA-approved options have established quality control and studied safety profiles.
For most healthy women with bothersome symptoms who begin hormone therapy before age 60 or within 10 years of menopause onset, major menopause societies consider the benefit-risk profile favorable when treatment is individualized. The 2002 WHI study created widespread fear of HRT, but subsequent reanalysis showed that the risks were concentrated in older women who started therapy well past menopause. Current evidence, supported by the Endocrine Society, NAMS, and ACOG, favors hormone therapy for appropriate candidates. Dr. Lampert evaluates your individual risk profile before prescribing.
Yes. This is one of the most common reasons patients come to Wellesley Medical. Perimenopause involves hormonal fluctuations, not consistently low levels. A single blood draw can catch you on a "normal" day while you're symptomatic most of the month. Dr. Lampert diagnoses and treats based on your full clinical picture, not just a snapshot lab value.
All consultations are conducted via secure video. Dr. Lampert takes a detailed history, reviews any prior labs or records, and develops your treatment plan during the initial evaluation. Lab orders are sent to a draw center near you. Prescriptions go directly to your pharmacy. Follow-up visits happen on the same platform. Menopause care is well suited to telehealth because the evaluation is primarily history-driven, and ongoing management is based on symptom tracking and periodic lab review.
Author: Seth Lampert, MD — Founding Physician & Medical Director, Wellesley Medical
Medical review date: October 2026
This page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information provided is not a substitute for consultation with a qualified physician. Individual evaluation is required before any treatment decisions are made. If you are experiencing a medical emergency, call 911.